As a relatively new medication to treat hyperkalemia, the effectiveness of sodium polystyrene sulfonate (SPS) is compared to sodium zirconium cyclosilicate (SZC) in the emergency department in this Journal Club discussion.

Upon successful completion of this application-based course, participants should be able to:
1. Review the emergent treatment of hyperkalemia
2. Identify the role of cation exchange resins in the emergent treatment of hyperkalemia
3. Compare the pharmacology and potassium lowering efficacy of sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC)
4. Evaluate the strengths, limitations, and results of the SPS vs SZC study for the treatment of hyperkalemia
5. Apply clinical implications of the SPS vs SZC study to a patient case 

Samantha Katzman, PharmD
Clinical Pharmacist Specialist
Emergency Medicine
U of L Health – Jewish Hospital

Dr. Katzman has no relevant financial relationships with ineligible companies to disclose. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below.

Hasara S, Dubey J, Amatea J, et al. Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department. Am J Emerg Med 2022;65:59-64. https:// DOI: 10.1016/j.ajem.2022.12.043

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Membership. To get more courses like this sent to you every month, sign-up!

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: March 8, 2023
Planned Expiration Date: March 8, 2026

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

RV1-10.23